Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00486382 |
Recruitment Status
:
Completed
First Posted
: June 14, 2007
Last Update Posted
: April 3, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Visceral Leishmaniasis Post-kala-azar Dermal Leishmaniasis | Biological: Leish-111f + MPL-SE Adjuvant | Phase 1 |
The purpose of this study is to determine the safety, tolerability, and immunogenicity of an investigational vaccine being developed for immunotherapy of visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL). The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f) together with adjuvant MPL-SE.
The primary objective is to evaluate the safety and tolerability of the Leish-111f + MPL-SE vaccine given as three subcutaneous injections every 28 days at each of three dose levels of the Leish-111f protein (5 μg, 10 μg, or 20 μg) together with MPL-SE adjuvant (25 μg) in healthy adults.
The secondary objective is to assess the immunogenicity of the vaccine by evaluating T-cell and antibody response to the Leish-111f protein of the vaccine.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India |
Study Start Date : | April 2007 |
Actual Primary Completion Date : | November 2008 |
Actual Study Completion Date : | November 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Low dose
Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
|
Biological: Leish-111f + MPL-SE Adjuvant |
Experimental: Medium dose
Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
|
Biological: Leish-111f + MPL-SE Adjuvant |
Experimental: High dose
Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
|
Biological: Leish-111f + MPL-SE Adjuvant |
- Injection site reactions [ Time Frame: For 7 days following each injection. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 54 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males and females ≥ 18 years and < 55 years of age.
- Must be in good general health as confirmed by a medical history and physical exam.
- DAT titer must be <1:400 and rK39 serology negative (for inclusion in the DAT-negative group) or DAT titer ≥1:1600 (for inclusion in the DAT-positive group).
- The following laboratory blood tests must have values within the normal ranges at screening (Appendix 4): sodium, potassium, urea, ALT, AST, total bilirubin, creatinine, alkaline phosphatase, glucose, hemoglobin, total WBC count and platelet count.
- The following serology tests must be negative at screening: HIV 1/2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All subjects will receive HIV related counseling prior to testing. Subjects with positive HIV test results will receive counseling at the University and will be referred to the national AIDS control program for treatment if appropriate.
- Subjects must give written informed consent, be willing and able to attend all required visits, have a permanent address, and be reachable by study site personnel.
- Female subjects of childbearing potential must have a negative urine pregnancy test at screening, a negative urine pregnancy test within 24 hours before study injection, must not be breast-feeding, and are required to use adequate contraception through Day 84 of the study. These precautions are necessary due to unknown effects that Leish-111f + MPL-SE might have in a fetus or newborn infant.
Exclusion Criteria:
- Previous exposure to Leishmania vaccines or experimental products containing MPL-SE.
- Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first administration of study injection.
- Known use of injected or oral corticosteroids within 6 weeks prior to the first administration of study injection.
- History of autoimmune disease or other causes of immunosuppressive states.
- History or evidence of any acute or chronic illness that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Potential subjects presenting with concomitant illness will be referred for clinical care.)
- History of use of any medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.
- History of significant psychiatric illness.
- Known to be a current drug or alcohol abuser.
- Subjects with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.
- History of chronic headaches or migraine.
- Subjects who are unlikely to cooperate with the requirements of the study protocol.
- Subjects who are not permanent residents or who are planning to move to another town/city.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00486382
India | |
Banaras Hindu University | |
Varanasi, Uttar Pradesh, India, 221 005 |
Principal Investigator: | Shyam Sundar, MD | Banaras Hindu University | |
Study Director: | Franco M Piazza, MD, MPh | IDRI |
Responsible Party: | IDRI |
ClinicalTrials.gov Identifier: | NCT00486382 History of Changes |
Other Study ID Numbers: |
IDRI-LVVPX-104 |
First Posted: | June 14, 2007 Key Record Dates |
Last Update Posted: | April 3, 2015 |
Last Verified: | April 2015 |
Keywords provided by IDRI:
visceral leishmaniasis vaccine |
Additional relevant MeSH terms:
Leishmaniasis Leishmaniasis, Visceral Euglenozoa Infections Protozoan Infections Parasitic Diseases Skin Diseases, Parasitic |
Skin Diseases, Infectious Skin Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |